Trubion Pharmaceuticals Inc.
2401 4th Avenue
Suite 1050
Seattle,
WA 98121
United States - Map
Phone: 206-838-0500
Fax: 206-838-0503
Web Site: http://www.trubion.com
| Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells. The company was founded in 1999 and is headquartered in Seattle, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Steven S. Gillis M.D., 56
Exec. Chairman and Acting Pres |
$
32.00K | N/A | Dr. Kendall Mohler Ph.D., 53
Co-Founder and Sr. VP of R&D |
$
276.00K | N/A | Ms. Michelle G. Burris , 43
Chief Operating Officer and senior vice president |
$
323.00K | N/A | Ms. Kathleen M. Deeley , 57
Sr. VP, Sec. and Gen. Counsel |
$
260.00K | N/A | Mr. Scott C. Stromatt M.D., 51
Chief Medical Officer and Sr. VP |
$
108.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
Profile
